期刊
CANCER GENE THERAPY
卷 18, 期 12, 页码 871-883出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/cgt.2011.56
关键词
surgery; esophageal carcinoma; neoadjuvant therapy; immunotherapy; animal models
类别
资金
- American Medical Association Foundation
- Lavin Family Supporting Foundation
- National Institutes of Health [K12CA076931]
- National Institutes of Health (Center for Molecular Studies in Digestive and Liver Diseases) [P30-DK050306]
- NCI [P01-CA098101]
Esophageal carcinoma is the most rapidly increasing tumor in the United States and has a dismal 15% 5-year survival. Immunotherapy has been proposed to improve patient outcomes; however, no immunocompetent esophageal carcinoma model exists to date to test this approach. We developed two mouse models of esophageal cancer by inoculating immunocompetent mice with syngeneic esophageal cell lines transformed by cyclin-D1 or mutant HRAS(G12V) and loss of p53. Similar to humans, surgery and adjuvant chemotherapy (cisplatin and 5-fluorouracil) demonstrated limited efficacy. Gene-mediated cyototoxic immunotherapy (adenoviral vector carrying the herpes simplex virus thymidine kinase gene in combination with the prodrug ganciclovir; AdV-tk/GCV) demonstrated high levels of in vitro transduction and efficacy. Using in vivo syngeneic esophageal carcinoma models, combining surgery, chemotherapy and AdV-tk/GCV improved survival (P = 0.007) and decreased disease recurrence (P<0.001). Mechanistic studies suggested that AdV-tk/GCV mediated a direct cytotoxic effect and an increased intra-tumoral trafficking of CD8 T cells (8.15% vs 14.89%, P = 0.02). These data provide the first preclinical evidence that augmenting standard of care with immunotherapy may improve outcomes in the management of esophageal carcinoma. Cancer Gene Therapy (2011) 18, 871-883; doi:10.1038/cgt.2011.56; published online 26 August 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据